---
title: "國家衞健委：我國躍居全球新藥研發第二位"
description: "今天上午，國新辦舉行 “高質量完成 ‘十四五’ 規劃” 系列主題新聞發佈會，介紹 “十四五” 時期衞生健康工作發展成就。據介紹，我國在研新藥數量佔全球數量的比例超過 20%，躍居全球新藥研發第二位，舒格利單抗、恩沙替尼、谷美替尼等多款國產創新藥陸續獲批上市，填補了相應領域國產創新藥的空白。我國自主研發的抗腫瘤藥品澤布替尼已在多個國家獲批上市。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/256838859.md"
published_at: "2025-09-11T03:12:00.000Z"
---

# 國家衞健委：我國躍居全球新藥研發第二位

> 今天上午，國新辦舉行 “高質量完成 ‘十四五’ 規劃” 系列主題新聞發佈會，介紹 “十四五” 時期衞生健康工作發展成就。據介紹，我國在研新藥數量佔全球數量的比例超過 20%，躍居全球新藥研發第二位，舒格利單抗、恩沙替尼、谷美替尼等多款國產創新藥陸續獲批上市，填補了相應領域國產創新藥的空白。我國自主研發的抗腫瘤藥品澤布替尼已在多個國家獲批上市。

今天上午，國新辦舉行 “高質量完成 ‘十四五’ 規劃” 系列主題新聞發佈會，介紹 “十四五” 時期衞生健康工作發展成就。據介紹，我國在研新藥數量佔全球數量的比例超過 20%，躍居全球新藥研發第二位，舒格利單抗、恩沙替尼、谷美替尼等多款國產創新藥陸續獲批上市，填補了相應領域國產創新藥的空白。我國自主研發的抗腫瘤藥品澤布替尼已在多個國家獲批上市。

### Related Stocks

- [02616.HK - 基石藥業-B](https://longbridge.com/zh-HK/quote/02616.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone secures FDA clearance to begin CS2009 Phase II trial | CStone Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase II trial f | [Link](https://longbridge.com/zh-HK/news/276114397.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| New Aventon Ramblas ADV e-bike brings 100Nm torque and 90-mile range to the trails | Aventon has launched the Ramblas ADV, an electric hardtail mountain bike featuring a second-generation mid-drive motor w | [Link](https://longbridge.com/zh-HK/news/276356769.md) |
| Salmon Evolution Sets Date for 2025 Results as Land-Based Salmon Strategy Scales Up | Salmon Evolution ASA, listed on Oslo Børs under the ticker SALME, announced it will present its Q4 and full-year 2025 fi | [Link](https://longbridge.com/zh-HK/news/276442230.md) |
| KUB Coin (KUB) - Validators Vote - 20 Feb–08 Mar 2026 | KUB Chain is conducting a governance vote on the proposal for "Single-Tier Validators for Lowering Barriers & Boosting E | [Link](https://longbridge.com/zh-HK/news/276434774.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。